[go: up one dir, main page]

AR132909A1 - METHODS OF TREATMENT OF INFLAMMATORY DISEASES - Google Patents

METHODS OF TREATMENT OF INFLAMMATORY DISEASES

Info

Publication number
AR132909A1
AR132909A1 ARP240101472A ARP240101472A AR132909A1 AR 132909 A1 AR132909 A1 AR 132909A1 AR P240101472 A ARP240101472 A AR P240101472A AR P240101472 A ARP240101472 A AR P240101472A AR 132909 A1 AR132909 A1 AR 132909A1
Authority
AR
Argentina
Prior art keywords
methods
pharmaceutically acceptable
treatment
inflammatory diseases
formula
Prior art date
Application number
ARP240101472A
Other languages
Spanish (es)
Inventor
Mario G Cardozo
Zuojun Guo
Robert Joseph Moreau
Naomi S Rajapaksa
Meera Rao
David C Tully
Steffen Gressies
Kai Thede
Zachary K Sweeney
Original Assignee
Interline Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Interline Therapeutics Inc filed Critical Interline Therapeutics Inc
Publication of AR132909A1 publication Critical patent/AR132909A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente divulgación se refiere a compuestos de fórmula (1), como se define en el presente documento, y sus sales farmacéuticamente aceptables, y composiciones que los comprenden. También se describen métodos para tratar las enfermedades y trastornos descritos en el presente documento, con los compuestos de fórmula (1) y sus sales farmacéuticamente aceptables, y las composiciones que los comprenden. Un compuesto de fórmula (1). Una composición farmacéutica que comprende un compuesto de cualquiera de las reivindicaciones 1 - 18, o una sal farmacéuticamente aceptable del mismo, y uno o más excipientes farmacéuticamente aceptables.The present disclosure relates to compounds of formula (1), as defined herein, and their pharmaceutically acceptable salts, and compositions comprising them. Also described are methods of treating the diseases and disorders described herein, with the compounds of formula (1) and their pharmaceutically acceptable salts, and compositions comprising them. A compound of formula (1). A pharmaceutical composition comprising a compound of any one of claims 1-18, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

ARP240101472A 2020-06-09 2024-06-10 METHODS OF TREATMENT OF INFLAMMATORY DISEASES AR132909A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063472252P 2020-06-09 2020-06-09
US202363609168P 2023-12-12 2023-12-12

Publications (1)

Publication Number Publication Date
AR132909A1 true AR132909A1 (en) 2025-08-06

Family

ID=96877974

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP240101472A AR132909A1 (en) 2020-06-09 2024-06-10 METHODS OF TREATMENT OF INFLAMMATORY DISEASES

Country Status (1)

Country Link
AR (1) AR132909A1 (en)

Similar Documents

Publication Publication Date Title
AR128931A1 (en) COMPLEMENT B FACTOR INHIBITORS AND USES THEREOF
CO2019009423A2 (en) Piperidine Substituted MNK Inhibitors and Related Methods
MX2021011606A (en) Compounds targeting prmt5.
ECSP20069418A (en) HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS
CL2022000271A1 (en) Pyrazolo(3,4-b)pyrazine shp2 phosphatase inhibitors.
CL2022001739A1 (en) Substituted tricyclic compounds
CO2021015318A2 (en) Compounds and methods for the treatment of covid-19
DOP2024000039A (en) QUINOLINE DERIVATIVES AS ALFA4BETA7 INTEGRIN INHIBITORS
CL2022001741A1 (en) Cyclic compounds and methods of using same
CL2024001022A1 (en) Small molecules for cancer treatment
AR105808A1 (en) AMIDA COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
AR127470A1 (en) LRRK2 INHIBITORS
CO2021014210A2 (en) Pyrrole compounds
UY39181A (en) COMPOUNDS AND COMPOSITIONS FOR INHIBITING HIF2a ACTIVITY AND THEIR METHODS OF USE
MX2019006612A (en) IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS.
MX2025010799A (en) Acylsulfonamide kat6a inhibitors
AR133953A1 (en) COMPLEMENT FACTOR B INHIBITORS AND THEIR USES
CO2025003099A2 (en) Compounds for cancer treatment
AR126892A1 (en) SUBSTITUTED AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS
UY37745A (en) BICYCLIC COMPOUNDS 5.6 FUSIONATES AND COMPOSITIONS FOR THE TREATMENT OF PARASITARY DISEASES
AR132909A1 (en) METHODS OF TREATMENT OF INFLAMMATORY DISEASES
DOP2021000100A (en) CYCLIC TETRAMEROUS COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN / KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS.
MX2021012544A (en) NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF KIDNEY DISEASES.
AR128100A1 (en) COMPOUNDS FOR THE TREATMENT OF HAIR LOSS
MX2024009581A (en) N3-substituted uracil compounds as trpa1 inhibitors.